Biotech Values

[dewophile]

They are going to be watching for GBS very carefully in the real world regardless of any post marketing study. It’s the only practical approach given the rarity of the condition.
This same approach over time led to a warning for shingrix as an excess of 3 GBS cases per million doses was found. So postmerketing surveillance today seems to be pretty good IMO